01.002 RWE GS Apr 2022 B 02-05-2022

Real-world evidence review of long-acting injectable (LAI) versus oral antipsychotics (OA) in treating schizophrenia

  • Comprehensive literature review and meta-analysis of recent published real-world studies compared healthcare use, costs, and medication adherence in patients with schizophrenia treated with LAI versus OA in the United States
  • The lower medical costs offset the higher pharmacy costs, resulting in a non-significant difference in total healthcare costs
  • Taken together, these findings provide strong evidence on the clinical and economic benefits of LAI compared with OA for the treatment of schizophrenia in the real world
Click here to learn more.

About SVMPharma

SVMPharma is an innovative strategic consultancy and CRO, with a focus in Real World Evidence (RWE) for pharmaceutical and biotechnology companies. SVMPharma delivers clinical trials within UK and Europe.


DISTILL is a new EDC launched by SVMPharma. As a CRO discover the benefits of DISTILL as part of your service offering and take back control of your clinical trials. DISTILL allows you to develop and manage every aspect of your trials from start to finish. Move away from the restrictions and costs associated with legacy systems.

For more information, please visit and contact us at